Interest in the connection between gut health and skin health has shifted from a niche scientific topic to a mainstream research priority. Scientists have long recognised that the skin does not function in isolation.

Instead, it reflects a complex interplay of genetics, immune function, environment, lifestyle, and increasingly, the microbial communities living within the body. Among these, the gut microbiome has emerged as a powerful regulator of inflammation and immune balance, two processes that are central to many skin disorders.

A recent large-scale scoping review has brought renewed attention to this link. Drawing on more than 500 studies involving both humans and animals, researchers set out to map the existing evidence on how orally consumed probiotics, prebiotics, and synbiotics affect skin health, function, and disease outcomes.

The review, published in a peer-reviewed nutrition science journal, Nutrition Reviews, aims not to provide definitive answers but to explore the scope, focus, potentials and limitations of the research landscape as it stands today.

Probiotics are defined as live microorganisms that, when consumed in adequate amounts, confer a health benefit. Prebiotics are specific dietary substances that favour the growth or activity of beneficial microorganisms already present in the gut. Synbiotics combine both elements in a single formulation.

Each has been studied for potential roles in digestive health, immune modulation, and metabolic conditions. Their relevance to dermatology has gained momentum over the past decade.

To capture this growing body of work, the researchers examined six major scientific databases alongside clinical trial registries and grey literature sources. Both published and unpublished studies were considered, regardless of whether they had undergone peer review. Topical products targeting the skin microbiome were deliberately excluded, allowing the focus to remain on orally delivered supplements and their systemic effects.

In total, 516 animal and human studies were included, along with seven secondary analyses linked to those trials. Infants emerged as the most frequently studied population, followed by adults aged 60 and under. This age distribution reflects the strong emphasis on early-life interventions, particularly in relation to allergic skin disease.

When disease prevention was examined, studies largely focused on supplementation during pregnancy, breastfeeding, or infancy. In contrast, investigations into general skin health and function tended to involve adults and older adults. Studies addressing disease management showed a clear skew towards children and adolescents. According to the review, two-thirds of the available evidence on disease management outcomes involved participants aged 18 or younger.

Animal research made up a substantial proportion of the dataset. Nearly 90 per cent of these studies were conducted in mice, highlighting both the value and limitation of preclinical models. While animal experiments allow for controlled exploration of mechanisms, their relevance to human skin conditions remains imperfect.

Among human studies, probiotics dominated the research field. Over 200 trials assessed oral probiotics, compared with 34 examining prebiotics and 41 evaluating synbiotics. The most commonly studied probiotic genus was Lactobacillus, a group widely used in commercial supplements and fermented foods.

The structure of the studies revealed notable patterns. Around two-thirds of human trials included fewer than 100 participants. Nearly 63 per cent focused on individuals with established skin diseases rather than healthy populations. In most cases, the supplement under investigation was the sole intervention, without concurrent changes to diet or lifestyle. The median intervention period was 12 weeks, a relatively short timeframe for conditions that often follow a chronic or relapsing course.

Eczema, also known as atopic dermatitis, dominated the outcome measures. Slightly more than half of all outcomes assessed related either to the prevention or management of this condition. Other outcomes included markers of skin health and function, such as hydration, elasticity, wrinkles, and response to ultraviolet exposure.

Overall, the evidence was most abundant for atopic dermatitis. The next most studied areas related to skin ageing and photoaging parameters. Smaller bodies of research explored acne and psoriasis. Conditions such as skin cancer, rosacea, melasma, alopecia, and pigment disorders were represented only sparsely.

Despite these gaps, many studies reported encouraging results. Among experimental and observational studies focused on eczema management, 72 per cent identified at least one positive outcome associated with probiotic or synbiotic use. In prevention studies, 54 per cent reported favourable effects. Trials investigating acne severity also observed beneficial outcomes in some cases, particularly with specific probiotic strains.

Evidence synthesis studies added further weight to these findings. Almost all systematic reviews included in the scoping analysis examined the prevention or management of skin conditions. The majority of meta-analyses suggested that probiotic supplementation could reduce the risk or severity of atopic dermatitis, especially when administered during pregnancy or early life.

Experts in dermatology and nutritional science have described the findings as both promising and cautionary. Imbalances in the microbiome are widely recognised as contributors to inflammatory diseases, including chronic skin conditions. For this reason, clinicians have already integrated probiotics into some treatment strategies, particularly in paediatric eczema. The review reinforces this practice while highlighting the need for better standardisation.

At the same time, the authors emphasise important limitations. As a scoping review, the study did not assess the quality or risk of bias of individual trials. Instead, it aimed to provide a broad overview. This approach allows for mapping trends but requires careful interpretation of conclusions.

Several factors may have influenced the results. The researchers used a specific definition of prebiotics, which may have excluded substances included under older or alternative definitions. Changes in microbial classification over time also created inconsistencies across studies. Additionally, the review did not address potential adverse effects unrelated to skin outcomes, an important consideration for clinical practice.

Conflicts of interest were disclosed in several included studies, reflecting a broader issue in supplement research. Commercial involvement can shape study design, reporting, and publication practices. Less than 20 per cent of human experimental studies reported participant ethnicity, limiting the ability to assess how microbiome responses may differ across populations.

Geographical bias was also evident. A large proportion of studies originated from Europe and Asia. Asia accounted for the majority of animal research. Dietary patterns, cultural practices, and environmental exposures differ widely across regions, all of which influence the gut microbiome.

Another challenge lies in the uneven distribution of research across conditions and age groups. Acne studies, for example, tended to focus on older children and adolescents, while older adults were the least studied demographic overall. This imbalance restricts the generalisability of findings.

Systematic reviews included in the analysis were themselves limited by language restrictions and methodological variation. Many reported significant heterogeneity between studies, reflecting differences in strains, doses, intervention duration, and outcome measures. Details on participants’ habitual diets were often missing, despite growing recognition that diet plays a central role in shaping the microbiome.

Researchers involved in the review stress that clearer clinical guidance will require more consistent trial design. Standardisation of probiotic strains, dosing regimens, and outcome measures is essential. Without this, comparisons across studies remain difficult and the development of evidence-based guidelines remains slow.

Looking ahead, the authors outline several priorities for future research. For atopic dermatitis, they suggest that an umbrella review could help clarify consistency across existing meta-analyses. In areas such as skin cancer and under-studied inflammatory conditions, more high-quality randomised controlled trials in humans are needed.

Older adults represent a particularly important gap. Age-related changes in the gut microbiome and skin physiology may alter responses to supplementation, yet this group has received limited attention. Studies examining synbiotics also remain relatively scarce compared with those on probiotics alone.

Dietary patterns and geographical context were highlighted as essential considerations for future work. Microbial composition varies significantly with diet, and interventions effective in one population may not translate directly to another. Researchers also called for updated systematic reviews in areas such as acne, where enough trials now exist to support comprehensive evidence synthesis.

For the public, the message remains measured. While probiotic supplements show potential, especially for preventing or managing eczema, the evidence is not yet strong enough to support widespread use for many other skin conditions. Individuals considering these products should be aware of the limitations and discuss potential benefits and risks with healthcare professionals.

This expansive review underscores both progress and complexity. The gut–skin axis is no longer a speculative concept. It is a rapidly evolving field supported by a growing volume of scientific inquiry.

Yet, translating that knowledge into clear, reliable clinical advice will require careful, coordinated research efforts in the years ahead.